Article (Scientific journals)
Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts.
Cacciaglia, Raffaele; Salvadó, Gemma; Molinuevo, José Luis et al.
2022In Molecular Psychiatry, 27 (4), p. 2010 - 2018
Peer Reviewed verified by ORBi
 

Files


Full Text
s41380-022-01436-7.pdf
Publisher postprint (3.84 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Amyloid beta-Peptides; ApoE protein, human; Apolipoprotein E4; Apolipoproteins E; Biomarkers; tau Proteins; Apolipoprotein E4/genetics; Apolipoproteins E/metabolism; Biomarkers/metabolism; Brain/metabolism; Female; Humans; Male; Positron-Emission Tomography/methods; tau Proteins/metabolism; Alzheimer Disease/genetics; Alzheimer Disease/metabolism; Amyloid beta-Peptides/metabolism; Alzheimer Disease; Brain; Positron-Emission Tomography; Molecular Biology; Psychiatry and Mental Health; Cellular and Molecular Neuroscience; Automotive Engineering
Abstract :
[en] Amyloid (Aβ) pathology is the earliest detectable pathophysiological event along the Alzheimer's continuum, which can be measured both in the cerebrospinal fluid (CSF) and by Positron Emission Tomography (PET). Yet, these biomarkers identify two distinct Aβ pools, reflecting the clearance of soluble Aβ as opposed to the presence of Aβ fibrils in the brain. An open question is whether risk factors known to increase Alzheimer's' disease (AD) prevalence may promote an imbalance between soluble and deposited Aβ. Unveiling such interactions shall aid our understanding of the biological pathways underlying Aβ deposition and foster the design of effective prevention strategies. We assessed the impact of three major AD risk factors, such as age, APOE-ε4 and female sex, on the association between CSF and PET Aβ, in two independent samples of non-demented individuals (ALFA: n = 320, ADNI: n = 682). We tested our hypotheses both in candidate regions of interest and in the whole brain using voxel-wise non-parametric permutations. All of the assessed risk factors induced a higher Aβ deposition for any given level of CSF Aβ42/40, although in distinct cerebral topologies. While age and sex mapped onto neocortical areas, the effect of APOE-ε4 was prominent in the medial temporal lobe, which represents a target of early tau deposition. Further, we found that the effects of age and APOE-ε4 was stronger in women than in men. Our data indicate that specific AD risk factors affect the spatial patterns of cerebral Aβ aggregation, with APOE-ε4 possibly facilitating a co-localization between Aβ and tau along the disease continuum.
Disciplines :
Neurology
Author, co-author :
Cacciaglia, Raffaele ;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain. rcacciaglia@barcelonabeta.org ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain. rcacciaglia@barcelonabeta.org ; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), 28089, Madrid, Spain. rcacciaglia@barcelonabeta.org
Salvadó, Gemma ;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain
Molinuevo, José Luis;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), 28089, Madrid, Spain ; Universitat Pompeu Fabra, 08002, Barcelona, Spain
Shekari, Mahnaz;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), 28089, Madrid, Spain
Falcon, Carles;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBERBBN), 28089, Madrid, Spain
Operto, Gregory;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), 28089, Madrid, Spain
Suárez-Calvet, Marc ;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), 28089, Madrid, Spain ; Servei de Neurologia, Hospital del Mar, Barcelona, Spain
Milà-Alomà, Marta;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), 28089, Madrid, Spain
Sala, Arianna  ;  Université de Liège - ULiège > GIGA > GIGA Consciousness - Coma Science Group ; Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, 141 52, Stockholm, Sweden
Rodriguez-Vieitez, Elena ;  Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Karolinska Institutet, 141 52, Stockholm, Sweden
Kollmorgen, Gwendlyn;  Roche Diagnostics GmbH, Penzberg, Germany
Suridjan, Ivonne;  Roche Diagnostics International Lda, Rotkreuz, Switzerland
Blennow, Kaj;  Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 41390, Mölndal, Sweden ; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 41390, Mölndal, Sweden
Zetterberg, Henrik ;  Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 41390, Mölndal, Sweden ; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 41390, Mölndal, Sweden ; UK Dementia Research Institute at UCL, WC1E 6BT, London, UK ; Department of Neurodegenerative Disease, UCL Institute of Neurology, WC1N 3BG, London, UK
Gispert, Juan Domingo ;  Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, 08005, Barcelona, Spain. jdgispert@barcelonabeta.org ; Hospital del Mar Medical Research Institute (IMIM), 08005, Barcelona, Spain. jdgispert@barcelonabeta.org ; Universitat Pompeu Fabra, 08002, Barcelona, Spain. jdgispert@barcelonabeta.org ; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBERBBN), 28089, Madrid, Spain. jdgispert@barcelonabeta.org
Alzheimer’s Disease Neuroimaging Initiative
ALFA study
More authors (7 more) Less
Language :
English
Title :
Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts.
Publication date :
April 2022
Journal title :
Molecular Psychiatry
ISSN :
1359-4184
eISSN :
1476-5578
Publisher :
Springer Nature, England
Volume :
27
Issue :
4
Pages :
2010 - 2018
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
This publication is part of the ALFA study (ALzheimer’s and FAmilies). The authors would like to express their most sincere gratitude to the ALFA project participants, without whom this research would have not been possible. The authors would like to thank Roche Diagnostics International Ltd. for kindly providing the kits for the CSF analysis of ALFA+ participants and GE Healthcare for kindly providing [18F]flutemetamol doses of ALFA+ participants.The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). MSC receives funding from Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva programme grant IJC2018-037478-I). KB holds the Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences, and is supported by the Swedish Research Council (#2017-00915); the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243); and a grant (#ALFGBG-715986) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL.
Available on ORBi :
since 27 December 2023

Statistics


Number of views
1 (0 by ULiège)
Number of downloads
1 (0 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
4
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi